AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Prolyl 4-hydroxylase subunit alpha-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P13674

UPID:

P4HA1_HUMAN

Alternative names:

Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1

Alternative UPACC:

P13674; C9JL12; Q15082; Q15083; Q5VSQ5

Background:

Prolyl 4-hydroxylase subunit alpha-1, also known as Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1, plays a pivotal role in collagen synthesis. It catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences, a critical step in the maturation and stability of collagen molecules.

Therapeutic significance:

Understanding the role of Prolyl 4-hydroxylase subunit alpha-1 could open doors to potential therapeutic strategies. Its essential function in collagen synthesis makes it a potential target for treating disorders related to extracellular matrix abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.